This study investigates the safety and tolerability of an investigational medication in patients with EGFR-driven advanced solid tumors. The study focuses on how patients respond to this treatment.
The purpose of this study is to evaluate the investigational medication both alone and in combination with another treatment. It looks at how safe the medication is for patients and how well they can tolerate it.
- Who can participate: Adults with EGFR-driven advanced solid tumors and a performance status of 1 or less may participate. Participants must be willing to undergo biopsies.
- Study details: Participants will receive either the investigational medication alone or in combination with another treatment. Some may receive a placebo.
How understandable was the trial content above?
Hard to understand
Easy to understand